Triple chemo cocktail shows promise against tough pancreatic cancer
NCT ID NCT03915444
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also tracked side effects and tumor shrinkage. Results suggest this combo may improve survival, but larger studies are needed to confirm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nab-paclitaxel, cisplatin, and gemcitabine (three chemotherapy drugs given together)
What this could lead to
If successful, this combination could offer a new treatment option to help people with metastatic pancreatic cancer live longer.
What could go wrong
This is a small, early-phase trial (42 people) without a comparison group. The results may not apply to everyone, and the drugs can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
University of Miami
Miami, Florida, 33136, United States